Suggestions
Kara Bortone
Senior Director, Precision Medicine, Johnson & Johnson Innovative Medicine Business Development
Kara Bortone is the Senior Director of Business Development at Johnson & Johnson's Innovative Medicine division. In this role, she is responsible for leading efforts in acquisition and licensing, focusing on advancing the company's strategic goals within the healthcare sector.32
Educational Background
Kara holds a Bachelor of Science in Chemistry from the University of North Carolina at Chapel Hill and a PhD in Biochemistry from the University of Texas at Austin. This strong academic foundation supports her expertise in business development within the pharmaceutical industry.4
Professional Experience
With over 500 connections on LinkedIn, Kara has built a significant professional network. Her experience at Johnson & Johnson emphasizes her leadership in innovative medicine, where she plays a crucial role in shaping the company's approach to new therapies and technologies.12
Kara's work has also been highlighted in various professional forums, showcasing her contributions to discussions on precision medicine and healthcare innovation.32
Highlights
Coming together here in San Diego reminds us of The Janssen Pharmaceutical Companies of Johnson & Johnson’s guiding mission: bringing transformational medicines to patients and changing the trajectory of human health. My time with my colleagues and peers at the @ Biotechnology Innovation Organization #bio2022 conference has been an important reminder of not only why collaboration and common goals of the #pharma and #biotech communities are what will propel us forward, but also, what makes our team unique in bringing together the best talent, the best ideas and the best science to achieve our ambitious goals.
Core to our work is partnering with companies and leveraging #precisionmedicine and data solutions to support Janssen at all levels, end to end. From AI/ML powered discovery of potential drug targets at the pre-clinical phases of development, to real world data evidence generation in clinical trials to collect richer evidence sets as well as accelerate studies, we are challenging the way we think about #precisionmedicine and using #datascience to its fullest potential - for the future of #healthcare.
Excited to be on the ground at #BIO2022 with The Janssen Pharmaceutical Companies of Johnson & Johnson https://lnkd.in/gHfSvbue, where we are meeting with fellow industry leaders in #PrecisionMedicine, #Diagnostics and #DataScience to discuss ways of partnering in all aspects of #drugdiscovery, development and commercialization.
